12:00 AM
 | 
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Zelboraf vemurafenib regulatory update

The U.K.'s NICE issued final appraisal determinations recommending the use of melanoma drugs Yervoy ipilimumuab from Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.) and Zelboraf vemurafenib from Roche. NICE, which rebuffed Yervoy last year, now recommends Yervoy to treat advanced malignant melanoma in adults who have received prior therapy - its approved indication. NICE said BMS provided additional data supporting the...

Read the full 304 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >